Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 91Rituximab 80Specimen Handling 75Magnetic Resonance Spectroscopy 64Biopsy 59Doxorubicin 48Prednisone 47Vincristine 46venetoclax 38obinutuzumab 35fludarabine 34ibrutinib 29Lenalidomide 29Dexamethasone 27Cytarabine 27Methotrexate 25Etoposide 24prednylidene 23CT-P10 23zanubrutinib 22deltacortene 22blinatumomab 22acalabrutinib 22fludarabine phosphate 21Nivolumab 21merphos 18pembrolizumab 16Bendamustine Hydrochloride 16Mercaptopurine 15Calcium Dobesilate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
loncastuximab tesirine × Lymphoid × 30 days × Clear all
NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT05464719 2026-05-20

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma

NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05672251 2026-05-11

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡